Targeting Brd4 for cancer therapy: inhibitors and degraders
- PMID: 30542529
- PMCID: PMC6238758
- DOI: 10.1039/c8md00198g
Targeting Brd4 for cancer therapy: inhibitors and degraders
Abstract
Bromodomain-containing protein 4 (Brd4) plays an important role in mediating the expression of genes involved in cancers and non-cancer diseases such as inflammatory diseases and acute heart failure. Inactivating Brd4 or downregulating its expression inhibits cancer development, leading to the current interest in Brd4 as a promising anticancer drug target. Numerous Brd4 inhibitors have been studied in recent years and some of them are currently in various phases of clinical trials. Recently, selective degradation of target proteins by small bifunctional molecules (PROTACs) has emerged as an attractive drug discovery approach owing to the advantages it could offer over traditional small-molecule inhibitors. A number of Brd4 degraders have been reported and showed more efficient anticancer activities than just protein inhibition. In this review, we will discuss recent findings in the discovery and development of small-molecule inhibitors and degraders that target Brd4 as a potential anticancer agent.
Figures























Similar articles
-
An updated patent review of BRD4 degraders.Expert Opin Ther Pat. 2024 Oct;34(10):929-951. doi: 10.1080/13543776.2024.2400166. Epub 2024 Sep 4. Expert Opin Ther Pat. 2024. PMID: 39219068 Review.
-
Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.Bioorg Med Chem. 2020 Jan 1;28(1):115181. doi: 10.1016/j.bmc.2019.115181. Epub 2019 Nov 11. Bioorg Med Chem. 2020. PMID: 31767403
-
Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.Cell Death Discov. 2023 Dec 22;9(1):470. doi: 10.1038/s41420-023-01775-6. Cell Death Discov. 2023. PMID: 38135679 Free PMC article. Review.
-
Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.Biochem Biophys Res Commun. 2020 Jan 22;521(4):833-839. doi: 10.1016/j.bbrc.2019.11.007. Epub 2019 Nov 7. Biochem Biophys Res Commun. 2020. PMID: 31708096
-
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.Bioorg Chem. 2020 Jun;99:103817. doi: 10.1016/j.bioorg.2020.103817. Epub 2020 Apr 9. Bioorg Chem. 2020. PMID: 32361153
Cited by
-
Targeting epigenetic protein-protein interactions with small-molecule inhibitors.Future Med Chem. 2020 Jul;12(14):1305-1326. doi: 10.4155/fmc-2020-0082. Epub 2020 Jun 19. Future Med Chem. 2020. PMID: 32551894 Free PMC article. Review.
-
Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer.Front Oncol. 2023 Mar 9;13:1120828. doi: 10.3389/fonc.2023.1120828. eCollection 2023. Front Oncol. 2023. PMID: 36969062 Free PMC article. Review.
-
Targeting inducible epigenetic reprogramming pathways in chronic airway remodeling.Drugs Context. 2019 Oct 23;8:2019-8-3. doi: 10.7573/dic.2019-8-3. eCollection 2019. Drugs Context. 2019. PMID: 31692901 Free PMC article. Review.
-
A 'Goldmine' for digging cancer-specific targets: the genes essential for embryo development but non-essential for adult life.J Mol Cell Biol. 2020 Sep 1;12(9):669-673. doi: 10.1093/jmcb/mjaa024. J Mol Cell Biol. 2020. PMID: 32470104 Free PMC article. Review. No abstract available.
-
Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion.Acta Neuropathol Commun. 2024 Mar 18;12(1):42. doi: 10.1186/s40478-024-01746-7. Acta Neuropathol Commun. 2024. PMID: 38500181 Free PMC article.
References
-
- Ronen Marmorstein S. Y. R. Curr. Opin. Genet. Dev. 2001;11:155–161. - PubMed
-
- Jenuwein T., Allis C. D. Science. 2001;293:1074–1080. - PubMed
-
- Jaiprakash N. S. S., Sangshett N., Dehghan M. H. G., Shinde D. B. Mini-Rev. Med. Chem. 2013;13:1005–1026. - PubMed
-
- Zeng L., Zhou M. M. FEBS Lett. 2002:124–128. - PubMed
-
- Ferri E., Petosa C., McKenna C. E. Biochem. Pharmacol. 2016;106:1–18. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources